XML 32 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Patents and other intangible assets
12 Months Ended
Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]  
Patents and other intangible assets

6.

Patents and other intangible assets

Patents and other intangible assets are recorded at cost, or when acquired as a part of a business combination, at estimated fair value. These assets are amortized on a straight-line basis over the useful lives of the assets.

 

 

 

 

 

December 31,

 

(U.S. Dollars, in thousands)

 

Weighted Average Amortization Period

 

2018

 

 

2017

 

Cost

 

 

 

 

 

 

 

 

 

 

Patents

 

10 years

 

$

39,085

 

 

$

38,621

 

Developed technology

 

10 years

 

 

12,400

 

 

 

 

IPR&D

 

Indefinite

 

 

26,800

 

 

 

 

License and other

 

7 years

 

 

14,654

 

 

 

10,276

 

Trademarks—finite lived

 

9 years

 

 

840

 

 

 

533

 

 

 

9 years

 

 

93,779

 

 

 

49,430

 

Accumulated amortization

 

 

 

 

 

 

 

 

 

 

Patents

 

 

 

$

(35,016

)

 

$

(34,151

)

Developed technology

 

 

 

 

(827

)

 

 

 

IPR&D

 

 

 

 

 

 

 

 

License and other

 

 

 

 

(5,744

)

 

 

(4,625

)

Trademarks—finite lived

 

 

 

 

(295

)

 

 

(193

)

 

 

 

 

 

(41,882

)

 

 

(38,969

)

Patents and other intangible assets, net

 

 

 

$

51,897

 

 

$

10,461

 

 

Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment. Impairment testing is performed at least annually or when a triggering event occurs that could indicate a potential impairment. If and when development is complete, which generally occurs when regulatory approval to market a product is obtained, the associated assets are deemed finite-lived and are amortized over a period that best reflects the economic benefits provided by these assets.

 

In February 2019, the Company obtained FDA approval of the M6-C artificial cervical disc. As such, amortization of the IPR&D intangible asset attributable to these research and development activities will commence starting in February 2019, for which the Company expects to use a 10 year amortization period.

 

Amortization expense for intangible assets was $2.7 million, $1.8 million and $1.8 million for the years ended December 31, 2018, 2017 and 2016, respectively. Future amortization expense for intangible assets, including IPR&D, is estimated as follows:

 

(U.S. Dollars, in thousands)

 

Amortization

 

2019

 

$

6,604

 

2020

 

 

6,205

 

2021

 

 

6,146

 

2022

 

 

6,138

 

2023

 

 

5,495

 

Thereafter

 

 

21,309

 

Total

 

$

51,897